Is NAVB or SYRS more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Is SYRS or GNCA more profitable?

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Syros Pharmaceuticals N/A -3,369.56% -97.04% Genocea Biosciences N/A -182.88% -62.76%

Is PXMD or SYRS more profitable?

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Syros Pharmaceuticals N/A -3,369.56% -97.04%

Is ARDS or SYRS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Which has preferable valuation & earnings, GNCAQ or SYRS?

Genocea Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Syros Pharmaceuticals $386K 0.01 -$164.57M -$3.03 N/A

Is GNCAQ or SYRS more profitable?

Genocea Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Syros Pharmaceuticals (SYRS) Competitors

$0.0001 0.00 (0.00%)

As of 07/2/2026 03:01 PM Eastern

Compare

SYRS vs. NAVB, GNCA, PXMD, ARDS, and GNCAQ

Should you buy Syros Pharmaceuticals stock or one of its competitors? MarketBeat compares Syros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syros Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry.

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Syros Pharmaceuticals	Neutral

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Syros Pharmaceuticals (NASDAQ:SYRS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Genocea Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Genocea Biosciences	N/A	-182.88%	-62.76%

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Genocea Biosciences	Neutral

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

Summary

Genocea Biosciences beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Syros Pharmaceuticals	Neutral

PaxMedica has higher earnings, but lower revenue than Syros Pharmaceuticals. PaxMedica is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A

Summary

Syros Pharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Syros Pharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Syros Pharmaceuticals	Neutral

Aridis Pharmaceuticals has a beta of 44.97, meaning that its share price is 4,397% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Syros Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Syros Pharmaceuticals	Neutral

Genocea Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Genocea Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A

Genocea Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Summary

Syros Pharmaceuticals beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

Get Syros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

SYRS vs. The Competition

Export

Metric	Syros Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3K	$998.91M	$6.96B	$12.41B
Dividend Yield	N/A	4.84%	2.68%	6.63%
P/E Ratio	0.00	1.66	27.81	24.72
Price / Sales	0.01	110.34	554.07	111.02
Price / Cash	N/A	20.06	48.59	58.15
Price / Book	0.00	8.17	10.96	6.45
Net Income	-$164.57M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.93%	2.18%	1.36%
1 Month Performance	N/A	3.18%	4.54%	1.68%
1 Year Performance	N/A	50.41%	33.33%	23.97%

Syros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-99.6%	$3K	$386K	N/A	120
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2
ARDS Aridis Pharmaceuticals	N/A	$0.00 -75.0%	N/A	+0.0%	$5K	N/A	0.00	30	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRS) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syros Pharmaceuticals (SYRS) Competitors

SYRS vs. NAVB, GNCA, PXMD, ARDS, and GNCAQ

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Summary

How does Syros Pharmaceuticals compare to PaxMedica?

Summary

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Summary

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

SYRS vs. The Competition

Syros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syros Pharmaceuticals (SYRS) Competitors

SYRS vs. NAVB, GNCA, PXMD, ARDS, and GNCAQ

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Do insiders & institutionals have more ownership in NAVB or SYRS?

Is NAVB or SYRS more profitable?

Does the media prefer NAVB or SYRS?

Which has better earnings and valuation, NAVB or SYRS?

Which has more risk & volatility, NAVB or SYRS?

Summary

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Which has stronger valuation & earnings, SYRS or GNCA?

Is SYRS or GNCA more profitable?

Does the media favor SYRS or GNCA?

Do institutionals and insiders believe in SYRS or GNCA?

Which has more risk and volatility, SYRS or GNCA?

Summary

How does Syros Pharmaceuticals compare to PaxMedica?

Do institutionals and insiders have more ownership in PXMD or SYRS?

Is PXMD or SYRS more profitable?

Which has more risk & volatility, PXMD or SYRS?

Does the media refer more to PXMD or SYRS?

Which has higher earnings and valuation, PXMD or SYRS?

Summary

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Do insiders and institutionals believe in ARDS or SYRS?

Which has higher earnings and valuation, ARDS or SYRS?

Is ARDS or SYRS more profitable?

Does the media favor ARDS or SYRS?

Which has more volatility & risk, ARDS or SYRS?

Summary

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Do institutionals & insiders hold more shares of GNCAQ or SYRS?

Does the media prefer GNCAQ or SYRS?

Is GNCAQ or SYRS more profitable?

Which has preferable valuation & earnings, GNCAQ or SYRS?

Which has more risk & volatility, GNCAQ or SYRS?

Summary

New MarketBeat Followers Over Time

SYRS vs. The Competition

Syros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools